NXL:NASDAQNexalin Technology, Inc. Analysis

Technical outlook: Nexalin trades at $0.61, comfortably above its 20‑day ($0.393) and 50‑day ($0.398) SMAs but well below the 200‑day SMA ($0.748), signaling a longer‑term bearish bias. The RSI sits at 77, indicating an overbought condition, while the MACD remains bullish with a positive histogram. Volume is on an upward trend, yet the stock exhibits extreme 30‑day volatility (≈119%) and a high beta of 2.72, underscoring pronounced price swings.
Fundamental backdrop: The company’s revenue has collapsed by 63% YoY to $275k, and operating margins are deeply negative (-141%). Cash balances ($2.7 M) modestly cover the $13 M market cap, but free cash flow is sharply negative. No debt exists, but earnings are nil with a trailing EPS of -$0.46. Recent news highlights progress in the pivotal HALO™ Clarity trial, aiming for FDA submission in Q2 2026, which could serve as a catalyst if the study meets endpoints.